Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 13;5(3):278-288.
doi: 10.1016/j.ekir.2019.11.022. eCollection 2020 Mar.

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale

Affiliations

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale

Barry I Freedman et al. Kidney Int Rep. .

Abstract

Introduction: Much of the higher risk for end-stage kidney disease (ESKD) in African American individuals relates to ancestry-specific variation in the apolipoprotein L1 gene (APOL1). Relative to kidneys from European American deceased-donors, kidneys from African American deceased-donors have shorter allograft survival and African American living-kidney donors more often develop ESKD. The National Institutes of Health (NIH)-sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes.

Methods: APOLLO will evaluate outcomes from 2614 deceased kidney donor-recipient pairs, as well as additional living-kidney donor-recipient pairs and unpaired deceased-donor kidneys.

Results: The United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations, American Society of Transplantation, American Society for Histocompatibility and Immunogenetics, and nearly all U.S. kidney transplant programs, organ procurement organizations (OPOs), and histocompatibility laboratories are participating in this observational study. APOLLO employs a central institutional review board (cIRB) and maintains voluntary partnerships with OPOs and histocompatibility laboratories. A Community Advisory Council composed of African American individuals with a personal or family history of kidney disease has advised the NIH Project Office and Steering Committee since inception. UNOS is providing data for outcome analyses.

Conclusion: This article describes unique aspects of the protocol, design, and performance of APOLLO. Results will guide use of APOL1 genotypic data to improve the assessment of quality in deceased-donor kidneys and could increase numbers of transplanted kidneys, reduce rates of discard, and improve the safety of living-kidney donation.

Keywords: APOL1; African Americans; chronic kidney disease; graft failure; kidney transplantation; outcomes.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) organizational chart (developed using clker.com free clipart; http://www.clker.com/clipart-blank-gray-usa-map-white-lines-1.html). NIH, National Institutes of Health; OPO, organ procurement organization.

Comment in

References

    1. Israni A.K., Salkowski N., Gustafson S. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol. 2014;25:1842–1848. - PMC - PubMed
    1. Rao P.S., Schaubel D.E., Guidinger M.K. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88:231–236. - PubMed
    1. Genovese G., Friedman D.J., Ross M.D. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–845. - PMC - PubMed
    1. Tzur S., Rosset S., Shemer R. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128:345–350. - PMC - PubMed
    1. Freedman B.I., Limou S., Ma L. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am J Kidney Dis. 2018;72:S8–S16. - PMC - PubMed